End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

The symptoms of end-stage kidney disease include the inability to urinate, fatigue, headaches, loss of appetite, nausea, vomiting, bone pain, confusion, and concentration difficulties.

The End-Stage Kidney Disease pipeline market research report provides comprehensive information on the therapeutics under development for End-Stage Kidney Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for End-Stage Kidney Disease and features dormant and discontinued projects.

End-Stage Kidney Disease Pipeline Products Market Segmentation by Targets

The key targets in the End-Stage Kidney Disease pipeline products market are Coagulation Factor XI, D2 Dopamine Receptor, D3 Dopamine Receptor, Gelsolin, and Tryptophan 2,3 Dioxygenase.

End-Stage Kidney Disease Pipeline Products Market Analysis by Targets

For more target insights into the End-Stage Kidney Disease pipeline products market, download a free report sample

End-Stage Kidney Disease Pipeline Products Market Segmentation by Mechanisms of Action

The key mechanisms of action in the End-Stage Kidney Disease pipeline products market are Coagulation Factor XI Inhibitor, D2 Dopamine Receptor Antagonist, D3 Dopamine Receptor Antagonist, Gelsolin Replacement, and Tryptophan 2,3 Dioxygenase Inhibitor.

End-Stage Kidney Disease Pipeline Products Market Analysis by Mechanisms of Action

For more mechanisms of action insights into the End-Stage Kidney Disease pipeline products market, download a free report sample

End-Stage Kidney Disease Pipeline Products Market Segmentation by Routes of Administration

The key routes of administration in the End-Stage Kidney Disease pipeline products market are intravenous and subcutaneous.

End-Stage Kidney Disease Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights into the End-Stage Kidney Disease pipeline products market, download a free report sample

End-Stage Kidney Disease Pipeline Products Market Segmentation by Molecule Types

The key molecule types in the End-Stage Kidney Disease pipeline products market are monoclonal antibody, small molecule, antisense oligonucleotide, cell therapy, gene-modified cell therapy, and recombinant protein.

End-Stage Kidney Disease Pipeline Products Market Analysis by Molecule Types

For more molecule type insights into the End-Stage Kidney Disease pipeline products market, download a free report sample

Competitive Landscape

The leading players in the End-Stage Kidney Disease pipeline products market are Aronora Inc, Bayer AG, BioAegis Therapeutics Inc, Daiichi Sankyo Co Ltd, Eagle Pharmaceuticals Inc, Ionis Pharmaceuticals Inc, KidneyCure Ltd, and VESSL Therapeutics Ltd.

End-Stage Kidney Disease Pipeline Products Market Analysis by Players

To know more about the leading players in the End-Stage Kidney Disease pipeline products market, download a free report sample

End-Stage Kidney Disease Pipeline Products Market Report Overview

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) (Genito Urinary System And Sex Hormones).
• The pipeline guide reviews pipeline therapeutics for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) (Genito Urinary System and Sex Hormones) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) (Genito Urinary System and Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews the latest news related to pipeline therapeutics for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) (Genito Urinary System and Sex Hormones)

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) (Genito Urinary System And Sex Hormones).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.